Literature DB >> 11398810

Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans.

E Zuffi1, E Manaresi, G Gallinella, G A Gentilomi, S Venturoli, M Zerbini, M Musiani.   

Abstract

The immune response against parvovirus B19 is mainly directed against the two structural proteins, VP1 and VP2. The amino terminal half of the VP1 unique region has been shown to elicit a dominant immune response in humans, more effective than other linear epitopes and also it has been seen to contain significant neutralizing linear epitopes. Three overlapping recombinant peptides corresponding to amino acids 2-40 (VP1-A), amino acids 32-71 (VP1-B), and amino acids 60-100 (VP1-C) of the VP1 unique region were produced by a procaryotic expression system. These peptides were used as antigens in a Western blot assay to detect specific immunoglobulin G (IgG) in serum samples from blood donors of different age groups with documented signs of a past B19 infection. Fragment VP1-C appeared significantly immunodominant over the other peptides, reacting with specific IgG in 86% of serum samples. The fragment VP1-C corresponds to a sequence with a known neutralizing activity and seems able to elicit a long-lasting immune response because specific IgG were present in blood donors of all age groups. VP1-C would therefore appear to be an attractive candidate as a component of a subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398810     DOI: 10.1089/088282401750234529

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  17 in total

1.  Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine.

Authors:  Candida Fasano; Darja Kanduc
Journal:  Self Nonself       Date:  2011-04-01

2.  Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity.

Authors:  Carlos Ros; Marco Gerber; Christoph Kempf
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

Review 3.  Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development.

Authors:  Piyanki Das; Koustav Chatterjee; Nabanita Roy Chattopadhyay; Tathagata Choudhuri
Journal:  Virusdisease       Date:  2019-03-26

4.  Globoside Is Dispensable for Parvovirus B19 Entry but Essential at a Postentry Step for Productive Infection.

Authors:  Jan Bieri; Carlos Ros
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

5.  Identification and characterization of persistent human erythrovirus infection in blood donor samples.

Authors:  Daniel Candotti; Nermin Etiz; Armen Parsyan; Jean-Pierre Allain
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization.

Authors:  Claudia Bönsch; Christoph Zuercher; Patricia Lieby; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

7.  Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity.

Authors:  Claudia Bönsch; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  Antibodies against structural and nonstructural proteins of human bocavirus in human sera.

Authors:  Reza Shirkoohi; Rika Endo; Nobuhisa Ishiguro; Shinobu Teramoto; Hideaki Kikuta; Tadashi Ariga
Journal:  Clin Vaccine Immunol       Date:  2009-12-02

9.  Human parvovirus B19 VP1u Protein as inflammatory mediators induces liver injury in naïve mice.

Authors:  Tsai-Ching Hsu; Chun-Ching Chiu; Shun-Chih Chang; Hsu-Chin Chan; Ya-Fang Shi; Tzy-Yen Chen; Bor-Show Tzang
Journal:  Virulence       Date:  2015-12-02       Impact factor: 5.882

10.  The N-terminal 5-68 amino acids domain of the minor capsid protein VP1 of human parvovirus B19 enters human erythroid progenitors and inhibits B19 infection.

Authors:  Wei Zou; Kang Ning; Peng Xu; Xuefeng Deng; Fang Cheng; Steve Kleiboeker; Jianming Qiu
Journal:  J Virol       Date:  2021-05-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.